Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers

Digestive Diseases and Sciences

Volumn 55, Issue 6, 2010, Pages 1627-1636

  Nishino, Masafumi ^a   Sugimoto, Mitsushige ^a   Kodaira, Chise ^a   Yamade, Mihoko ^a   Shirai, Naohito ^b   Ikuma, Mutsuhiro ^a   Tanaka, Tatsuo ^a   Sugimura, Haruhiko ^a   Hishida, Akira ^a   Furuta, Takahisa ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Enshu General Hospital   (Japan)

Author keywords

CYP2C19; Microvessel; Proton pump inhibitor; Rabeprazole

Indexed keywords

ACETYLSALICYLIC ACID; BAYASPIRIN; CYTOCHROME P450 2C19; RABEPRAZOLE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; GASTRIC PH MONITORING; GENOTYPE; HISTOPATHOLOGY; HUMAN; LOW DRUG DOSE; MALE; OPEN STUDY; PRIORITY JOURNAL; SCORING SYSTEM; STOMACH MUCOSA INJURY; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYL HYDROCARBON HYDROXYLASES; ASPIRIN; BIOPSY; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; GASTRIC MUCOSA; GASTROSCOPY; GENOTYPE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; PHENOTYPE; PROTON PUMP INHIBITORS; SEVERITY OF ILLNESS INDEX; STOMACH ULCER; YOUNG ADULT;

EID: 77954423662     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-0920-3     Document Type: Article

References (32)

1. K Nishikawa T Sugiyama M Kato, et al. 2000 Non-Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population Eur J Gastroenterol Hepatol 12 6 635 640 10.1097/00042737-200012060-00010 1:STN:280: DC%2BD3M%2FivFaktQ%3D%3D 10912481 (Pubitemid 30433538)
2. EH Awtry J Loscalzo 2000 Aspirin Circulation 101 10 1206 1218 1:CAS:528:DC%2BD3cXit1aksL0%3D 10715270 (Pubitemid 30146625)
3. AS Taha WJ Angerson RP Knill-Jones O Blatchford 2005 Upper gastrointestinal haemorrhage associated with low-dose aspirin and anti-thrombotic drugs - a 6-year analysis and comparison with non-steroidal anti-inflammatory drugs Aliment Pharmacol Ther 22 4 285 289 10.1111/j.1365-2036. 2005.02560.x 1:CAS:528:DC%2BD2MXhtVGlt7rF 16097994 (Pubitemid 41207457)
4. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. Bmj. 1994;308(6921):81-106. (Pubitemid 24052591)
5. RT Schoen RJ Vender 1989 Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage Am J Med 86 4 449 458 10.1016/0002-9343(89)90344-6 1:CAS:528:DyaL1MXhvVGhsLg%3D 2648824 (Pubitemid 19103913)
6. F Halter 1988 Mechanism of gastrointestinal toxicity of NSAIDs Scand J Rheumatol Suppl 73 16 21 10.3109/03009748809104664 1:STN:280: DyaL1M%2FhvFWguw%3D%3D 3140370
7. ND Yeomans AI Lanas NJ Talley, et al. 2005 Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin Aliment Pharmacol Ther 22 9 795 801 10.1111/j.1365-2036.2005.02649.x 1:STN:280:DC%2BD2MrkvFWruw%3D%3D 16225488 (Pubitemid 41564359)
8. S Derry YK Loke 2000 Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis BMJ 321 7270 1183 1187 10.1136/bmj.321.7270.1183 1:CAS:528:DC%2BD3cXovVeltL8%3D 11073508
9. A Pilotto M Franceschi G Leandro, et al. 2004 Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs Aliment Pharmacol Ther 20 10 1091 1097 10.1111/j.1365-2036.2004.02246.x 1:CAS:528: DC%2BD2MXmtVanug%3D%3D 15569111 (Pubitemid 39657942)
10. P Serrano A Lanas MT Arroyo IJ Ferreira 2002 Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases Aliment Pharmacol Ther 16 11 1945 1953 10.1046/j.1365-2036.2002.01355.x 1:CAS:528:DC%2BD38XptFSqur8%3D 12390104 (Pubitemid 34407526)
11. T Furuta N Shirai M Sugimoto K Ohashi T Ishizaki 2004 Pharmacogenomics of proton pump inhibitors Pharmacogenomics 5 2 181 202 10.1517/phgs.5.2.181.27483 1:CAS:528:DC%2BD2cXivFantLc%3D 15016609 (Pubitemid 38351277)
12. T Furuta N Shirai M Takashima, et al. 2001 Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin Clin Pharmacol Ther 69 3 158 168 10.1067/mcp.2001.113959 1:CAS:528: DC%2BD3MXislylsbw%3D 11240980 (Pubitemid 32225416)
13. T Ishizaki Y Horai 1999 Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole Aliment Pharmacol Ther 13 Suppl 3 27 36 10.1046/j.1365-2036.1999.00022.x 1:CAS:528: DyaK1MXlvVGhurk%3D 10491726 (Pubitemid 29389409)
14. S Yasuda Y Horai Y Tomono, et al. 1995 Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status Clin Pharmacol Ther 58 2 143 154 10.1016/0009-9236(95)90192-2 1:CAS:528:DyaK2MXosF2ms7s%3D 7648764
15. K Adachi T Katsube A Kawamura, et al. 2000 CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole Aliment Pharmacol Ther 14 10 1259 1266 10.1046/j.1365-2036.2000.00840.x 1:CAS:528: DC%2BD3cXotV2jsb0%3D 11012469
16. N Shirai T Furuta Y Moriyama, et al. 2001 Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH Aliment Pharmacol Ther 15 12 1929 1937 10.1046/j.1365-2036.2001.01108.x 1:CAS:528:DC%2BD38Xks1SrtA%3D%3D 11736724 (Pubitemid 34014349)
17. I Ieiri Y Kishimoto H Okochi, et al. 2001 Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism Eur J Clin Pharmacol 57 6-7 485 492 1:CAS:528:DC%2BD3MXotlyku7c%3D 11699613 (Pubitemid 32930149)
18. Y Horai M Kimura H Furuie, et al. 2001 Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes Aliment Pharmacol Ther 15 6 793 803 10.1046/j.1365-2036.2001.00980.x 1:CAS:528:DC%2BD3MXks1Kitr4%3D 11380317 (Pubitemid 32500425)
19. FL Lanza GL Royer Jr RS Nelson TT Chen CE Seckman MF Rack 1981 A comparative endoscopic evaluation of the damaging effects of nonsteroidal anti-inflammatory agents on the gastric and duodenal mucosa Am J Gastroenterol 75 1 17 21 1:STN:280:DyaL3M3gsVentg%3D%3D 7234826
20. Y Naito T Yoshikawa S Iinuma, et al. 1998 Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study Dig Dis Sci 43 9 Suppl 83S 89S 1:CAS:528:DyaK1cXmsV2rsL0%3D 9753232 (Pubitemid 28433955)
21. MF Dixon RM Genta JH Yardley P Correa 1996 Classification, grading of gastritis. The updated Sydney System. International workshop on the histopathology of gastritis Houston, 1994 Am J Surg Pathol 20 10 1161 1181 10.1097/00000478-199610000-00001 1:STN:280:DyaK28visVGlsg%3D%3D 8827022 (Pubitemid 26336840)
22. J Svedlund I Sjodin G Dotevall 1988 GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease Dig Dis Sci 33 2 129 134 10.1007/BF01535722 1:STN:280: DyaL1c7htV2htg%3D%3D 3123181 (Pubitemid 18054672)
23. T Funatsu K Chono T Hirata Y Keto A Kimoto M Sasamata 2007 Mucosal acid causes gastric mucosal microcirculatory disturbance in nonsteroidal anti-inflammatory drug-treated rats Eur J Pharmacol 554 1 53 59 10.1016/j.ejphar.2006.10.023 1:CAS:528:DC%2BD28Xht1KksLrI 17112499 (Pubitemid 44820047)
24. SL Elliott RJ Ferris AS Giraud GA Cook MV Skeljo ND Yeomans 1996 Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH Clin Exp Pharmacol Physiol 23 5 432 434 10.1111/j.1440-1681.1996.tb02754.x 1:CAS:528:DyaK28XjtFahsbk%3D 8713684 (Pubitemid 26171549)
25. GK Kitchingman PJ Prichard TK Daneshmend RP Walt CJ Hawkey 1989 Enhanced gastric mucosal bleeding with doses of aspirin used for prophylaxis and its reduction by ranitidine Br J Clin Pharmacol 28 5 581 585 1:CAS:528: DyaK3cXjtVCmtA%3D%3D 2590612
26. V Savarino GS Mela P Zentilin, et al. 1998 Effect of one-month treatment with nonsteroidal antiinflammatory drugs (NSAIDs) on gastric pH of rheumatoid arthritis patients Dig Dis Sci 43 3 459 463 10.1023/A:1018834301901 1:CAS:528:DyaK1cXisVGisro%3D 9539637 (Pubitemid 28155563)
27. M Janssen LC Baak JB Jansen BA Dijkmans JP Vandenbroucke CB Lamers 1993 Effects of indomethacin on intragastric pH and meal-stimulated serum gastrin secretion in rheumatoid arthritis patients Aliment Pharmacol Ther 7 4 393 400 1:STN:280:DyaK2c%2Fjt12nsw%3D%3D 8218753 (Pubitemid 23267015)
28. M Odashima M Otaka M Jin, et al. 2006 Attenuation of gastric mucosal inflammation induced by aspirin through activation of A2A adenosine receptor in rats World J Gastroenterol 12 4 568 573 1:CAS:528:DC%2BD28XjsFyju7k%3D 16489670 (Pubitemid 43380787)
29. JL Wallace SR Zamuner W McKnight, et al. 2004 Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation Am J Physiol Gastrointest Liver Physiol 286 1 G76 G81 10.1152/ajpgi.00295.2003 1:CAS:528:DC%2BD2cXot1Wktg%3D%3D 14665439 (Pubitemid 38055839)
30. T Yao M Kato M Asaka 2007 Pathology of gastric mucosal injury induced by low-dose aspirin Gi Forefr 3 1 32 36 Japanese
31. T Kitahora PH Guth 1987 Effect of aspirin plus hydrochloric acid on the gastric mucosal microcirculation Gastroenterology 93 4 810 817 1:CAS:528:DyaL2sXlvFSmtLk%3D 3623024 (Pubitemid 17156007)
32. T Shimatani M Inoue T Kuroiwa, et al. 2005 Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry Dig Dis Sci 50 7 1202 1206 10.1007/s10620-005-2760-0 1:CAS:528:DC%2BD2MXmtlCktbc%3D 16047460 (Pubitemid 41184743)